These findings suggest that augmentation of brain GLP‐1 by NEP inhibitors may prevent AD development through modulation of brain glucose homeostasis, attenuation of brain IR and mitigation of neuroinflammation and oxidative stress (Figure 5). Here, GLP1R is linked to Alzheimer disease.